It was recently identified as a potential p53-MDM2 inhibitor and its anti-cancer effect in vitro was reported [29], but was never investigated in vitro in HCC cell lines, nor in vivo in nude mice, and its role as a potential CDK2 inhibitor remained unknown until now. Here, TP53 is linked to hepatocellular carcinoma.